Driving Viral Hepatitis Market Growth in 2025: The Role of Elevated Prevalence Of Hepatitis Driving Growth In The Viral Hepatitis Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Viral Hepatitis Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the size of the viral hepatitis market has experienced consistent growth. It is projected to increase from $16.21 billion in 2024 to $16.93 billion in 2025, representing a compound annual growth rate (CAGR) of 4.4%. Factors like the development of vaccines, implementation of blood screening programs, production of antiviral drugs, and global health initiatives have contributed to the growth observed in the historic period.

How Will the Viral Hepatitis Market Size Evolve and Grow by 2029?
Over the forthcoming years, the viral hepatitis market size is predicted to enjoy stable expansion, reaching a total of $19.97 billion in 2029 with a 4.2% compound annual growth rate (CAGR). This accelerated growth during the forecasted timeframe can be credited to various factors such as increased treatment accessibility, public health policies, combination treatments, and initiatives for health equality. The forecasted time period is also slated to observe key trends such as the implementation of customized treatment strategies, the incorporation of digital health instruments, artificial intelligence in disease tracking, and micro-elimination of hepatitis c.

View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

What Drivers Are Propelling the Growth of Viral Hepatitis Market Forward?
The escalating incidence of hepatitis is anticipated to fuel the expansion of the viral hepatitis market in the future. Hepatitis, a liver infection caused by an array of infectious viruses and non-infectious substances, could lead to numerous health complications. Hepatitis forms A, B, C, D, and E can initiate a viral hepatitis infection, leading to liver inflammation and potential damage. For example, the European Centre for Disease Prevention and Control reported in April 2024 that across 30 EU/EEA member countries, there were 28,855 documented instances of hepatitis B virus (HBV) infection in 2022. This reflected an increase of 78% from 16,187 cases in the previous year, 2021. Furthermore, the case count in 2022, which totaled 28,420, indicated a crude rate of 8.5 cases for every 100,000 residents. Thus, the growing incidence of hepatitis is spurring the viral hepatitis market's growth. A rise in the quantity of research and development activities is predicted to stimulate the expansion of the viral hepatitis market. Research and development (R&D) in the realm of viral hepatitis involves an assortment of activities, such as creating vaccines, formulating antiviral medications, developing diagnostic tests, conducting epidemiological studies, implementing public health measures, investigating genomic research, strategizing prevention methods, initiating global health programs, running clinical trials, and probing into co-infections. The escalation in research and development activities facilitates treatment innovation, diversification of diagnosis and prevention choices, an increase in clinical trials, improved global health initiatives, and heightened competition among pharmaceutical entities. For instance, Melbourne researchers secured $1.7 million in hepatitis B cure-research funding for the subsequent five years via the mRNA Victoria Activation Program in November 2022, according to The Peter Doherty Institute for Infection and Immunity. Therefore, the viral hepatitis market's growth is being propelled by the amplification in the quantity of research and development activities.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Which Emerging Trends Are Transforming the Viral Hepatitis Market in 2025?
Organizations in the viral hepatitis market are strategizing on new drug advancements and developments to maintain their market significance. The process of drug innovation boosts the scientific understanding of disease mechanisms and fast-tracks the growth of new therapeutic solutions. To illustrate, Gilead Sciences Inc., a biopharmaceutical firm from the US, in November 2022, made it known that the FDA had approved their al new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This is to be used as a daily treatment for chronic hepatitis B virus (HBV) infection in children aged 12 years or above who have compensated liver disease. The approval came on the back of the successful results of a 24-week Phase 2 clinical trial for Vemlidy among this particular pediatric group.

What Are the Key Segments in the Viral Hepatitis Market?
The viral hepatitis market covered in this report is segmented -

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A
2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D, Hepatitis E

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp

Who Are the Key Players Shaping the Viral Hepatitis Market's Competitive Landscape?
Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

What Geographic Markets Are Powering Growth in the Viral Hepatitis Market?
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.